What's new

Another Breakthrough in Epidemic Prevention! The Team at Kaohsiung Medical University Has Developed a COVID-19 Antibody Testing Platform for Precise Assessment of Antibody Efficacy

Yuanta Securities has been appointed as the recommended securities firm for AMS BioteQ Emerging Stock Board since February 25, 2022!

AMS BioteQ Chairman, Dr. Yi-Ju Tsai (center), and the team are actively conducting research to develop potential new drugs and address the unmet topical medication market.
Antibiotic-Resistant Superbug – one of the greatest threats to human health.

AMS BioteQ focuses its research and development efforts on three key stages: “novel compound development,” “patent in research and development technology,” and “new drug research and development.”

Dressings play a crucial role in accelerating wound healing.

In the research and development of oral medication for Wuhan pneumonia (novel coronavirus disease, COVID-19), the Taiwanese biotechnology industry is actively involved.

The Good News in the Development of New Drugs for COVID-19! A New Type of Antibiotic Has Shown Effective Virus Suppression

As the COVID-19 pandemic subsides, there’s positive news regarding the first antibiotic developed by a Taiwanese biotech company to inhibit the coronavirus.

As the global COVID-19 pandemic continues, despite ongoing vaccination efforts in various countries, many risks and concerns remain.